Eli Lilly's Cancer Drug Olomoborib Receives FDA Orphan Drug Designation
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Eli Lilly's (LLY) experimental pancreatic cancer treatment, Olomoborib, marking a significant milestone in the company's expansion beyond weight-loss drugs.
S. Food and Drug Administration (FDA) granted orphan drug designation to the company’s experimental pancreatic cancer treatment Olomoborib. The development comes as Lilly, known for its blockbuster diabetes and weight-loss medicines, continues to push deeper into oncology.